".........The study compared aortic flow haemodynamics in five patients who had received a DurAVRTM valve against other transcatheter aortic valve implants (TAVI) and patients who had surgical aortic valve replacement (SAVR). The study results demonstrated the novel leaflet design of DurAVRTM THV restored ascending aortic flow haemodynamics, whereas SAVR and other TAVI valves did not demonstrate the same physiological advantage."
I can't get over this statement in bold in the quarterly . We are better than the gold standard of SAVR. Imagine that
- Forums
- ASX - By Stock
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
AVR
anteris technologies global corp.
Add to My Watchlist
0.65%
!
$6.08

".........The study compared aortic flow haemodynamics in five...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$6.08 |
Change
-0.040(0.65%) |
Mkt cap ! $94.85M |
Open | High | Low | Value | Volume |
$6.01 | $6.08 | $6.01 | $9.92K | 1.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1624 | $6.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.07 | 190 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1624 | 6.000 |
2 | 878 | 5.860 |
2 | 195 | 5.850 |
1 | 857 | 5.830 |
1 | 900 | 5.780 |
Price($) | Vol. | No. |
---|---|---|
6.080 | 450 | 2 |
6.150 | 2710 | 2 |
6.180 | 50 | 1 |
6.200 | 1000 | 1 |
6.400 | 130 | 1 |
Last trade - 11.13am 26/06/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online